{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Hormone Therapy Agent[C147908]" in comments (approximate match)
Status:
US Previously Marketed
Source:
FLUOXYMESTERONE by WATSON LABS
(1983)
Source URL:
First approved in 1956
Source:
HALOTESTIN by PHARMACIA AND UPJOHN
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Fluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is a synthetic, orally active androgenic-anabolic steroid (AAS) and a 17α-alkylated derivative of testosterone developed by Pharmacia & Upjohn Company LLC, approved by FDA at 1956. Fluoxymesterone is used in the treatment of hypogonadism in males and breast cancer in women. Fluoxymesterone has a relatively high ratio of androgenic to anabolic activity similarly to testosterone. Like many 17α-alkylated AAS, it has a relatively low affinity for the androgen receptor (AR). However, its actions are mediated by the AR, most likely due to its relatively long elimination half-life of approximately 9.2 hours.
Status:
First approved in 1953
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
STANOLONE, also known as dihydrotestosterone, is a potent androgenic metabolite of testosterone and anabolic agent for systemic use. It may be used as a replacement of male sex steroids in men who have androgen deficiency, for example as a result of the loss of both testes, and also the treatment of certain rare forms of aplastic anemia which are or may be responsive to anabolic androgens.
Status:
First approved in 1952
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
METHALLENESTRIL, an allenolic acid derivative, is a synthetic nonsteroidal estrogen used to treat menstrual issues.
Status:
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
IOTHIOURACIL, in a form of sodium salt, was used as an antithyroid agent in the treatment of hyperthyroidism. It is selectively incorporated into the melanin pigment of melanomas during biosynthesis by serving as false melanin precursors. Radiolabelled (125I) IOTHIOURACIL may be used as a radiopharmaceutical for diagnosis and therapy of melanotic melanomas.
Status:
First approved in 1951
Class (Stereo):
CHEMICAL (ABSOLUTE)
Methandriol is an anabolic steroid. Methandriol is classified as a weak anabolic with weak androgenic properties. Methandriol displays some level of estrogenic activity, making this steroid less useful for dieting. The drug is generally considered too mild and is not widely popular among bodybuilders and athletes. It seems most prominent in Australia now, where it remains included in a number of veterinary anabolic steroid products.
Status:
US Previously Marketed
Source:
TACE by SANOFI AVENTIS US
(1982)
Source URL:
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Chlorotrianisene (TACE®) is a powerful synthetic, non-steroidal estrogen used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. It may also be used to prevent breast engorgement following childbirth. Chlorotrianisene (TACE®) binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
Status:
US Previously Marketed
Source:
Precursone by Wyeth
(1951)
Source URL:
First approved in 1950
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Pregnenolone sulfate is an endogenous neurosteroid with excitatory effects in the brain, acting as a potent negative allosteric modulator of the GABAA receptor, a positive allosteric modulator of the NMDA receptor, and activator of transient receptor potential cation channel TRPM1 and TRPM3. In the model of schizophrenia, treatment with pregnenolone sulfate normalized the hyperlocomotion and stereotypic bouts, and rescued the PPI deficits of dopamine transporter knockout mice. Promnesic properties of pregnenolone sulfate were demonstrated in rat models of spatial memory performance.
Status:
US Previously Marketed
Source:
MEPRANE DIPROPIONATE by R&C
(1961)
Source URL:
First approved in 1947
Class (Stereo):
CHEMICAL (MIXED)
Methestrol is a nonsteroidal synthetic estrogen that has never been marketed.
Status:
US Previously Marketed
Source:
DV by SANOFI AVENTIS US
(1982)
Source URL:
First approved in 1947
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Dienestrol (INN, USAN) (brand names Ortho Dienestrol, Dienoestrol, Dienoestrol Ortho, Sexadien, Denestrolin, Dienol, Dinovex, Follormon, Oestrodiene, Synestrol, numerous others) is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva. Conditions that are treated with vaginal estrogens include a genital skin condition (vulvar atrophy), inflammation of the vagina (atrophic vaginitis), and inflammation of the urethra (atrophic urethritis). Dienestrol currently discontinued in US, but still in market in some other counties
Status:
First approved in 1942
Class (Stereo):
CHEMICAL (MIXED)
Benzestrol (originally called 118B and Octofollin), synthetic nonsteroidal estrogen and analog of stilbestrol, was used for oral estrogenic therapy for women and in order to prevent premature births. Besides, benzestrol gave most of the patients’ satisfactory relief of their estrogen deficiency symptoms. However, its use has been discontinued.